"The voice for cancer physicians and their patients in Massachusetts."

  • 14 Jan 2019 3:08 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved romiplostim (Nplate; Amgen) for pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Read full press release

  • 14 Jan 2019 3:02 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda; Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). Read full press release.

  • 14 Jan 2019 2:26 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved olaparib (Lynparza; AstraZeneca Pharmaceuticals) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Read full press release.

  • 14 Jan 2019 2:02 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved ravulizumab-owvz (Ultomiris; Alexion Pharmaceuticals, Inc.) for adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Read full press release

  • 21 Sep 2018 10:55 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved ibrutinib (Imbruvica; Pharmacyclics) plus rituximab (Rituxan) for the treatment of adult patients with Waldenstrom's macroglobulinemia (WM). Read full press release. 

  • 21 Sep 2018 8:13 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved moxetumomab pasudoltox-tdfk (Lumoxiti; AstraZeneca Pharmaceuticals), a CD22-directed cytotoxin indicated for adult patients with relapased or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). Read full press release. 

  • 29 Jun 2018 10:46 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved encorafenib and binimetinib (Braftovi and Mektovi; Array BioPharma) in combination for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, as detected by an FDA-approved test. Read full press release.

  • 29 Jun 2018 10:41 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved bevacizumab (Avastin; Genentech) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplat and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection. Read full press release. 

  • 29 Jun 2018 10:31 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda; Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. Read full press release.

  • 29 Jun 2018 9:43 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted regular approval to venetoclax (Venclexta; AbbVie and Genentech) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Read full press release.

Upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software